Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.43 |
| ▸ | SYK | P43405 | 1/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.40 |
| ▸ | CSF1R | P07333 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 2/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.37 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.37 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.37 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.37 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3720028 | 0.90 | GSK3B (0.42) | DYRK1AGSK3BHRH3TGFBR1ACHE | |
| SCHEMBL3718443 | 0.88 | ACVR1 (0.41) | DYRK1AGSK3BHRH3PIK3CAPIK3CD | |
| SCHEMBL3664246 | 0.84 | CLK2 (0.39) | SYKDYRK1A | |
| SCHEMBL3662940 | 0.83 | EGFR (0.36) | DYRK1AHRH3PDE4B | |
| SCHEMBL3722068 | 0.82 | DYRK1A (0.43) | DYRK1AGSK3BACHETBK1 | |
| SCHEMBL4186447 | 0.82 | DYRK1A (0.37) | DYRK1AHRH3 | |
| SCHEMBL3796221 | 0.78 | PRKCQ (0.43) | PRMT6HRH3JAK1JAK2TGFBR1 | |
| SCHEMBL3714748 | 0.78 | TGFBR1 (0.46) | DYRK1AGSK3BHRH3TGFBR1ACHE | |
| SCHEMBL3662671 | 0.77 | EGFR (0.37) | DYRK1A | |
| SCHEMBL3663103 | 0.76 | TGFBR1 (0.51) | PRMT6SYKDYRK1AGSK3BHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2242742-B1 | PYRIDINE DERIVATIVES | NOVARTIS AG (CH) | 2015-12-02 | — | — | EP | disclosed |
| US-8343966-B2 | Organic compounds | NOVARTIS AG (CH) | 2013-01-01 | — | — | US | disclosed |
| US-20090215776-A1 | Organic compounds | ADCOCK CLAIRE | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215776-A1 | Organic compounds | REN, RXFP1, MYLK | PRMT6 983/4885SYK 1085/4885DYRK1A 4748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.